ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

Malone Retires As NIH Deputy, Raub To Succeed Him

August 22, 1986

NCCN Updates Myeloma Clinical Practice Guidelines

September 26, 2003

Insurance Co. Official Says Cancer Centers, Insurers Are “Allies”

June 2, 1995

Vogel To Succeed Yates As VP for Research At American Cancer Society.

October 17, 2008

Gleevec First Pediatric Cancer Approval By FDA In 13 Years

May 30, 2003

Erbitux Improves Survival In Advanced Colorectal Cancer

November 30, 2007